Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
Top Page
Allogene Therapeutics
(NASDAQ:ALLO)
Select Model
Select Model
Rating:51Neutral
Price Target:
$2.50
▼(-4.58% Downside)
Action:ReiteratedDate:03/25/26
The score is held back primarily by very weak financial performance (minimal revenue, persistent losses, and sustained cash burn). Offsetting this, the latest earnings call points to meaningful upcoming catalysts and an extended cash runway, while technicals are moderately supportive with an intermediate uptrend but limited near-term momentum. Valuation metrics provide little support due to negative earnings and no dividend.
Positive Factors
Scalable off-the-shelf model & clinical footprint
Allogene's allogeneic 'off-the-shelf' CAR-T model and >60-site SemiCell footprint support scalable trial enrollment and community/outpatient deployment. That infrastructure can lower manufacturing lead times and per-patient costs, improving long-term commercial scalability versus autologous approaches.
Negative Factors
Persistent negative operating and free cash flow
Allogene consistently converts accounting losses into real cash outflows, with materially negative operating and free cash flow annually. Sustained burn erodes assets and equity, increasing dependence on external financing; long-term viability hinges on successful trial outcomes or repeat capital raises, raising dilution and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Scalable off-the-shelf model & clinical footprint
Allogene's allogeneic 'off-the-shelf' CAR-T model and >60-site SemiCell footprint support scalable trial enrollment and community/outpatient deployment. That infrastructure can lower manufacturing lead times and per-patient costs, improving long-term commercial scalability versus autologous approaches.
Read all positive factors
Allogene Therapeutics (ALLO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$638.70M
Dividend YieldN/A
Average Volume (3M)5.62M
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue Growth-100.00%
EPS Growth37.10%
CountryUS
Employees226
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.17
Shares Outstanding243,777,920
10 Day Avg. Volume7,038,465
30 Day Avg. Volume5,624,865
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-2.02
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-17.96
Enterprise Value/Ebitda-3.70
Forecast
1Y Price Target
$8.83Price Target Upside237.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.8
Revenue Forecast (FY)$13.85K
Allogene Therapeutics Business Overview & Revenue Model
Company Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic...
How the Company Makes Money
Allogene Therapeutics is a clinical-stage company and does not have recurring product sales from commercialized therapies. Its revenue has primarily been generated from collaboration and licensing arrangements, including payments related to partne...
Allogene Therapeutics Earnings Call Summary
Earnings Call Date:Mar 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 06, 2026
Earnings Call Sentiment Positive
The call presented multiple high-impact near-term catalysts (April MRD readout for ALPHA-3 and June proof-of-concept data for ALLO-329), a differentiated autoimmune approach with potential low/no lymphodepletion, and an extended cash runway into 2028 to support prioritized programs. However, the company faces meaningful financial losses, dependence on surrogate MRD endpoints with incomplete linkage to clinical outcomes, competitive headwinds from frontline bispecifics, and uncertainty around safety and small-sample interim analyses. On balance, the call emphasized execution readiness and funding to reach key inflection points while acknowledging important clinical and market risks.Positive Updates
Upcoming Clinical Catalysts and Timelines
ALPHA-3 (SemiCell) interim futility MRD analysis planned for April 2026 on 24 patients (12 per arm); ALLO-329 proof-of-concept translational and early clinical signals expected in June 2026; additional clinical updates anticipated later in 2026.
Negative Updates
Ongoing and Material Net Losses
Net loss for FY2025 was $190.9 million (or $0.87 per share); Q4 2025 net loss was $38.8 million (or $0.17 per share), underscoring continued cash burn and reliance on capital markets to bridge to clinical inflection points.
Read all updates
Q4-2025 Updates
Positive
Negative
Upcoming Clinical Catalysts and Timelines
ALPHA-3 (SemiCell) interim futility MRD analysis planned for April 2026 on 24 patients (12 per arm); ALLO-329 proof-of-concept translational and early clinical signals expected in June 2026; additional clinical updates anticipated later in 2026.
Read all positive updates
Company Guidance
The company reiterated financial and clinical guidance: as of 12/31/2025 cash, cash equivalents and investments were $258.3M, plus an additional $23.7M received from escrow in February and $20.7M raised year-to-date via ATM, extending runway into 2028 (said to cover ALPHA-3 enrollment); Q4 R&D was $28.6M (including $2.5M non‑cash stock‑based compensation) and FY R&D was $150.2M (incl. $12.9M SBC); Q4 G&A was $13.8M (incl. $5.6M SBC) and FY G&A was $56.8M (incl. $24.7M SBC); net loss Q4 was $38.8M or $0.17/sh and net loss FY was $190.9M or $0.87/sh (incl. $37.6M SBC and $2.4M impairment). For 2026 they guided operating cash expense of ~ $150M and GAAP operating expenses of ~ $210M (including ~ $35M non‑cash SBC), excluding BD impacts. Key clinical milestones: an ALPHA‑3 interim futility MRD analysis in April on 24 patients (12 per arm) with an anchored target 25–30 percentage‑point absolute delta in MRD clearance, >60 active U.S./Canada sites (Australia and South Korea start‑ups underway) and modeled spontaneous MRD clearance of ~20% in the observation arm; and ALLO‑329 proof‑of‑concept translational and early clinical signals expected in June 2026 from the RESOLUTION Phase 1 (3+3) study starting at 20M CAR T cells in parallel cohorts with cyclophosphamide‑only and no lymphodepletion (noting competitor doses up to ~5–10x autologous and ~50x other allogeneic).Allogene Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
23
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 22.00K | 95.00K | 156.00K | 114.09M |
| Gross Profit | -12.36M | 22.00K | 95.00K | -14.14M | 114.09M |
| EBITDA | -194.57M | -243.33M | -313.07M | -321.24M | -169.74M |
| Net Income | -190.89M | -257.59M | -327.26M | -340.41M | -182.05M |
Balance Sheet | |||||
| Total Assets | 415.90M | 548.71M | 642.84M | 821.58M | 1.05B |
| Cash, Cash Equivalents and Short-Term Investments | 250.21M | 292.48M | 448.70M | 517.32M | 457.30M |
| Total Debt | 75.05M | 90.76M | 95.12M | 101.12M | 73.13M |
| Total Liabilities | 123.36M | 126.53M | 130.60M | 154.70M | 125.63M |
| Stockholders Equity | 292.54M | 422.18M | 512.23M | 666.88M | 925.20M |
Cash Flow | |||||
| Free Cash Flow | -149.63M | -200.99M | -239.25M | -225.71M | -206.26M |
| Operating Cash Flow | -149.25M | -200.30M | -237.73M | -220.52M | -184.81M |
| Investing Cash Flow | 95.56M | 75.69M | 163.29M | 106.16M | 163.66M |
| Financing Cash Flow | 30.16M | 116.67M | 95.69M | 2.95M | 11.96M |
Allogene Therapeutics Technical Analysis
Positive
2.62
Price Trends
2.18
Positive
1.81
Positive
1.51
Positive
Market Momentum
0.08
Negative
58.37
Neutral
77.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALLO, the sentiment is Positive. The current price of 2.62 is above the 20-day moving average (MA) of 2.40, above the 50-day MA of 2.18, and above the 200-day MA of 1.51, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 58.37 is Neutral, neither overbought nor oversold. The STOCH value of 77.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALLO.
Allogene Therapeutics Risk Analysis
Allogene Therapeutics disclosed 78 risk factors in its most recent earnings report. Allogene Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allogene Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $638.70M | -1.58 | -57.07% | ― | -100.00% | 37.10% | |
49 Neutral | $274.41M | 3.92 | 53.18% | ― | ― | ― | |
45 Neutral | $291.74M | -4.58 | 105.48% | ― | -3.91% | 37.89% | |
44 Neutral | $144.87M | -1.20 | -85.20% | ― | ― | 46.68% | |
44 Neutral | $387.75M | -1.23 | -113.81% | ― | ― | 20.71% |
* Healthcare Sector Average
ALLO
Allogene Therapeutics
2.62
1.26
92.65%
ABEO
Abeona Therapeutics
4.81
0.49
11.34%
FHTX
Foghorn Therapeutics
4.97
1.76
54.83%
TNYA
Tenaya Therapeutics
0.67
0.25
60.34%
NMRA
Neumora Therapeutics, Inc.
2.13
1.41
195.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.